Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.69 |
| ▸ | ITGA2B | P08514 | 17/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.47 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.47 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346439 | 1.00 | ITGB3 (0.69) | ITGB3ITGA2BALOX15F2PRSS1 | |
| SCHEMBL8783382 | 0.86 | ITGB3 (0.68) | ITGB3ITGA2BALOX15F2PRSS1 | |
| SCHEMBL8783409 | 0.86 | ITGB3 (0.68) | ITGB3ITGA2BALOX15F2PRSS1 | |
| Hydrochloric Acid SCHEMBL8784282 | 0.86 | ALOX15 (0.70) | ITGB3ITGA2BALOX15F2PRSS1 | |
| Hydrochloric Acid SCHEMBL8034192 | 0.85 | ALOX15 (0.69) | ITGB3ITGA2BALOX15F2PRSS1 | |
| Hydrochloric Acid SCHEMBL8783790 | 0.85 | ALOX15 (0.69) | ITGB3ITGA2BALOX15F2PRSS1 | |
| Hydrochloric Acid SCHEMBL8783744 | 0.84 | ALOX15 (0.66) | ITGB3ITGA2BALOX15F2PRSS1 | |
| SCHEMBL6839445 | 0.82 | ITGB3 (1.00) | ITGB3ITGA2BALOX15F2PRSS1 | |
| SCHEMBL7346450 | 0.81 | ITGB3 (0.45) | ITGB3ITGA2BALOX15 | |
| SCHEMBL7346457 | 0.81 | ITGB3 (0.45) | ITGB3ITGA2BALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0612313-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1994-08-31 | — | — | EP | claimed |
| WO-1993010091-A2 | PIPERIDINE ACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1993-05-27 | — | — | WO | claimed |
| EP-0542363-A2 | Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation | GLAXO GROUP LIMITED (GB) | 1993-05-19 | — | — | EP | claimed |
| US-20030118584-A1 | Restoration of platelet aggregation by antibody administration after GPIIB/IIIa antagonist treatment | G.D. SEARLE & CO. | 2003-06-26 | — | — | US | disclosed |
| US-20020177172-A1 | RESTORATION OF PLATELET AGGREGATION BY ANTIBODY ADMINISTRATION AFTER GPIIB/IIIA ANTAGONIST TREATMENT | WESTERN MICHIGAN UNIVERSITY | 2002-11-28 | — | — | US | disclosed |
| EP-0912901-B1 | METHOD AND REAGENT FOR MONITORING BLOOD LEVELS OF ANTIPLATELET COMPOUNDS | SEARLE & CO (US) | 2001-11-07 | — | — | EP | disclosed |
| US-6150114-A | Method and reagent for monitoring blood levels of antiplantelet compounds | G. D. SEARLE & CO. (US) | 2000-11-21 | — | — | US | disclosed |
| EP-0912901-A1 | METHOD AND REAGENT FOR MONITORING BLOOD LEVELS OF ANTIPLATELET COMPOUNDS | G.D. SEARLE & CO. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997043650-A1 | METHOD AND REAGENT FOR MONITORING BLOOD LEVELS OF ANTIPLATELET COMPOUNDS | G.D. SEARLE & CO. (US) | 1997-11-20 | — | — | WO | disclosed |
| EP-0542363-A2 | Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation | GLAXO GROUP LIMITED (GB) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118584-A1 | Restoration of platelet aggregation by antibody administration after GPIIB/IIIa antagonist treatment | F13B, GP6, FGB | ITGB3 12/4885ITGA2B 10/4885ALOX15 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.